GenePOC proud to announce $5.7 million GAPP partnership to support development and commercialization of two new tests on its POC platform

GenePOC Inc., a Canadian company developing cost-effective and rapid molecular devices to detect pathogen genes at Point-of-Care, is pleased to announce that its project, in partnership with Université Laval, was successful in securing funding from Genome Canada and Génome Québec through the Genomic Applications Partnership Program (GAPP).

The project, entitled “New test to rapidly diagnose infections”, aims to support the development and commercialization of two new tests for the rapid diagnostic of infections. The GAPP program partners academic researchers with “users” of genomics to support projects that address real world challenges and opportunities.

“This funding from the Canadian government provides an opportunity for GenePOC to leverage the broad genomic expertise from the labs of Dr Michel G. Bergeron” said Patrice Allibert, PhD, CEO GenePOC. “ The first two assays developed by GenePOC, namely Group B Strep (GBS) and Clostridium Difficile (C.diff.), are scheduled to enter clinical trials validation within the next weeks. This project will help accelerate the development of our assay menu and will increase the attractiveness of our offer.”

Click here to read the detailed press release and background information from Genome Canada.

Click here to read the press release from Génome Québec